Zeng has over 15 years of academic expertise in the development of stem cell technologies and its applications
Axol Bioscience, a biotechnology company, specialising in the use of stem cell technology to manufacture disease relevant cell based assay systems to the drug discovery industry, has appointed Xianmin Zeng as the Chief Scientific Officer. Zeng has over 15 years of academic expertise in the development of stem cell technologies and its applications. She is a well – established and internationally-recognised leader in the creation of disease models for drug discovery.
With Zeng as Axol’s CSO, the company will be able to continue to offer highly-validated products and further improve upon their current processes under her expert guidance. As a key opinion leader in the field, she will offer strategic direction to help drive Axol’s product development, so as to address some of the vital challenges in the drug discovery industry.
Yichen Shi, PhD, CEO, Axol Bioscience said, ‘Prof Zeng is recognised globally for her wealth of experience working with both human ESCs and iPSCs. Her insight and expertise in stem cell technologies, drug discovery and neurodegenerative disease modelling will be of enormous value to the innovative work we do here at Axol. We are delighted to have Prof Zeng on board as our CSO and look forward to expanding our portfolio of highly-validated stem cells and services.”
EP News Bureau – Mumbai